Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845. doi: 10.1007/s00432-020-03236-4. Epub 2020 May 14.


Purpose: The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients.

Methods: Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session.

Results: The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available.

Conclusion: This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.

Keywords: Cytoreductive nephrectomy; Immunotherapy; Recommendations; Renal cell carcinoma; Treatment.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell / diagnosis*
  • Carcinoma, Renal Cell / therapy*
  • Clinical Decision-Making
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures / methods
  • Disease Management
  • Expert Testimony
  • Humans
  • Kidney Neoplasms / diagnosis*
  • Kidney Neoplasms / therapy*
  • Latin America
  • Metastasectomy / methods
  • Nephrectomy / methods
  • Practice Guidelines as Topic
  • Standard of Care